Trial
NCT04322643
Intermittent Checkpoint Inhibitor Therapy In Patients With Advanced Urothelial Carcinoma
Phase IITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Case Comprehensive Cancer Center
Collaborators
—
Condition
Urothelial Carcinoma
Intervention
Pembrolizumab
Why stopped
PI preference
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-02-25